封面
市场调查报告书
商品编码
1463298

全球基因分型市场规模、份额、成长分析,按类型(微阵列、聚合酶炼式反应 (PCR))、按应用(製药和生物製药公司、诊断实验室和诊所)- 2024-2031 年行业预测

Global Genotyping Market Size, Share, Growth Analysis, By Type(Microarray, Polymerase Chain Reaction (PCR)), By Application(Pharmaceutical and Biopharmaceutical Companies, Diagnostic Laboratories and Clinics) - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年全球基因分型市场规模为214.3亿美元,预计将从2023年的261.4亿美元成长到2031年的1,283.1亿美元,在预测期内(2024-2031年)复合年增长率为22%。

对基因检测、个人化医疗和基因组学研究进展的日益增长的需求正在推动全球基因分型市场的强劲扩张。基因异常频率的增加、早期疾病诊断知识的增加以及精准医学的进步是推动市场发展的一些原因。在科学和治疗领域,经常采用聚合酶炼式反应 (PCR)、次世代定序 (NGS) 和微阵列等基因分型技术。此外,由于基因分型资料与资料分析和生物资讯技术的结合,市场正在扩大。为了在全球基因分型市场中获得更大份额,该行业的主要竞争对手正在专注于产品创新、基因检测产品多样化以及建立策略联盟。

目录

执行摘要

  • 市场概况
  • 命运之轮

研究方法论

  • 资讯采购
  • 二手和主要资料来源
  • 市场规模估计
  • 市场假设与限制

母公司市场分析

  • 市场概况
  • 市场规模
  • 市场动态
    • 司机
    • 机会
    • 限制
    • 挑战

主要市场洞察

  • 技术分析
  • 定价分析
  • 供应链分析
  • 价值链分析
  • 市场生态系统
  • 智慧财产权分析
  • 贸易分析
  • 启动分析
  • 原料分析
  • 创新矩阵
  • 管道产品分析
  • 总体经济指标
  • 顶级投资分析
  • 成功的关键因素
  • 竞争程度

市场动态与展望

  • 市场动态
    • 司机
    • 机会
    • 限制
    • 挑战
  • 监管环境
  • 波特分析
  • 对未来颠覆的特别见解

按类型分類的全球基因分型市场

  • 市场概况
  • 微阵列
  • 聚合酶炼式反应 (PCR)
  • 定序
  • 其他的

按应用分類的全球基因分型市场

  • 市场概况
  • 製药和生物製药公司
  • 诊断实验室和诊所
  • 研究所和学术中心
  • 和别的

按地区分類的全球基因分型市场规模

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 拉丁美洲其他地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • MEA 的其余部分

竞争格局

  • 前 5 名玩家比较
  • 2021 年关键参与者的市场定位
  • 主要市场参与者所采取的策略
  • 最佳制胜策略
  • 近期市集活动
  • 主要公司市占率(%),2021年

主要公司简介

  • Thermo Fisher Scientific Inc. (United States)
  • Illumina, Inc. (United States)
  • QIAGEN NV (Netherlands)
  • Agilent Technologies, Inc. (United States)
  • Bio-Rad Laboratories, Inc. (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Danaher Corporation (United States)
  • PerkinElmer, Inc. (United States)
  • Fluidigm Corporation (United States)
  • Eurofins Scientific (Luxembourg)
  • Luminex Corporation (United States)
  • Pacific Biosciences of California, Inc. (United States)
  • Oxford Nanopore Technologies Ltd. (United Kingdom)
  • Affymetrix, Inc. (United States)
  • Genewiz (United States)
  • GENEWIZ Germany GmbH (Germany)
  • Bioline Reagents Ltd. (United Kingdom)
  • Genomic Health, Inc. (United States)
  • Takara Bio Inc. (Japan)
  • Agena Bioscience, Inc. (United States)
简介目录
Product Code: SQMIG35D2088

Global Genotyping Market size was valued at USD 21.43 billion in 2022 and is poised to grow from USD 26.14 billion in 2023 to USD 128.31 billion by 2031, growing at a CAGR of 22% during the forecast period (2024-2031).

The increasing need for genetic testing, personalized medicine, and advances in genomics research are driving the robust expansion of the global genotyping market. Growing frequency of genetic abnormalities, increased knowledge of early illness diagnosis, and advancements in precision medicine are some of the reasons driving the market. In both scientific and therapeutic contexts, genotyping technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and microarrays are frequently employed. Furthermore, the market is expanding due to the incorporation of genotyping data with data analytics and bioinformatics technologies. To gain a bigger share of the worldwide genotyping market, major competitors in the industry are concentrating on product innovation, diversifying their genetic testing offerings, and forging strategic alliances.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genotyping Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Genotyping Market Segmental Analysis

The Global Genotyping Market is segmented by type, application, and region. Based on type, the market can be segmented into microarray, polymerase chain reaction (pcr), sequencing, and others. Based on application, the market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic laboratories and clinics, research institutes and academic centers, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Genotyping Market

Growing need for customized treatment and the rising incidence of genetic disorders are two major factors propelling the worldwide genotyping industry. Finding genetic variants, mutations, and gene sequences that may be connected to certain illnesses or treatment reactions is made possible in large part by genotyping. Thanks to developments in genomics and our growing knowledge of genetic markers, genotyping now allows for individualized medication choices, diagnosis, and treatments. The growing need for precision medicine techniques and genotyping technologies is fueled by the increased frequency of hereditary illnesses.

Restraints in the Global Genotyping Market

The ethical and privacy issues surrounding genetic testing are a major barrier to the worldwide genotyping market. The availability of a person's genetic information gives rise to worries around potential abuse or misunderstanding of that information. The broad use of genotyping is hampered by concerns about permission, data security, and the possibility of discrimination based on genetic information. In addition, great thought must go into how genetic test findings are interpreted and shared with patients and medical professionals in order to guarantee correct comprehension and the right course of action. It is essential to address these privacy and ethical issues in order to foster involvement, foster confidence, and advance the responsible use of genotyping technology.

Market Trends of the Global Genotyping Market

The growing need for precision healthcare and tailored medication is a major trend in the worldwide genotyping market. In order to detect genetic variants and markers linked to different diseases and treatment responses, genotyping is essential. Researchers and healthcare professionals now have more access to genotyping thanks to advances in genomic technologies and genotyping's declining cost. Based on a person's genetic profile, genotyping enables customized treatment regimens that lead to more focused medicines, better disease management, and better patient outcomes. The potential for customized therapies and our increasing understanding of the genetic underpinnings of disease are what are driving this development. Healthcare is being revolutionized by genotyping because it allows for more targeted and efficient interventions based on each person's own genetic profile.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Genotyping Market by Type

  • Market Overview
  • Microarray
  • Polymerase Chain Reaction (PCR)
  • Sequencing
  • and Others

Global Genotyping Market by Application

  • Market Overview
  • Pharmaceutical and Biopharmaceutical Companies
  • Diagnostic Laboratories and Clinics
  • Research Institutes and Academic Centers
  • and Others

Global Genotyping Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Thermo Fisher Scientific Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Illumina, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • QIAGEN N.V. (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agilent Technologies, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Rad Laboratories, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche Ltd (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Danaher Corporation (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PerkinElmer, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fluidigm Corporation (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eurofins Scientific (Luxembourg)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Luminex Corporation (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pacific Biosciences of California, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Oxford Nanopore Technologies Ltd. (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Affymetrix, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genewiz (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GENEWIZ Germany GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bioline Reagents Ltd. (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genomic Health, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takara Bio Inc. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agena Bioscience, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments